Caption Management 13F: Adds $2M to BMRN Stake

Caption Management Expands BioMarin Holding

Caption Management boosted its stake in BioMarin Pharmaceutical Inc. NasdaqGS:BMRN during the period, according to a Form 13F filing with the U.S. Securities and Exchange Commission. The filing reflects holdings as of the reporting date and may not represent the investor's current position today. The fund increased its position by a 183.6% margin, buying an additional 35,800 shares to finish the quarter with 55,300 shares.

The recent portfolio move brought the total reported value of the holding to roughly $3.16 million based on the fund's reported cost basis. This expansion follows earlier activity from other institutional managers tracking the biotechnology company, such as Mariner increasing its own stake earlier in the year.

BioMarin Stock Trades Near 200-Day Average

BioMarin Pharmaceutical shares recently changed hands at $57.22. The stock trades near its 200-day moving average of $58.37, while sitting below its 50-day moving average of $63.78. Over the past year, the shares have moved between a low of $49.26 and a high of $70.98. The company has a forward P/E ratio of 9.68 and a total market capitalization of approximately $12.40 billion.

Recent Earnings and Financial Health

In its most recent financial reports, BioMarin posted $3.41 billion in trailing revenue with a revenue growth rate of 19.9%. The biotechnology firm reported earnings per share of $0.37, along with a net margin of 2.14% and a return on equity of 1.18%. Investors will monitor the company's next earnings report scheduled for October 26, 2026, for further updates on financial performance and rare disease therapy sales.

Wall Street Analyst Updates

Research firms have kept active coverage on BioMarin shares through late summer and autumn. On October 14, 2026, Barclays maintained an Overweight rating on the stock while raising its price target to $114.00 from $111.00. Earlier on September 10, 2026, HC Wainwright & Co. maintained a Neutral rating with a $60.00 price target. Piper Sandler maintained an Overweight rating on September 1, 2026, lifting its target to $90.00 from $88.00. Jefferies kept a Buy rating on August 31, 2026, with a target of $105.00, while HC Wainwright & Co. maintained its Neutral rating at $60.00 earlier that same day. Overall, the stock carries a consensus buy recommendation from analysts.

Focus on Rare Disease Therapeutics

Headquartered in San Rafael, California, BioMarin focuses on creating and commercializing treatments for rare and life-threatening medical conditions. Its portfolio targets specialized markets globally, making institutional accumulation a closely watched indicator for sector sentiment. Because 13F filings look backward, investors often review these disclosures alongside newer insider transactions and analyst updates to gauge institutional confidence.